Elafibranor has ‘significant, sustained treatment benefit’ in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.
“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease progression in PBC, in addition to alleviating quality of life-impacting symptoms,” Christelle Huguet, executive vice president of research and development at Ipsen, told Healio. “Elafibranor,

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.
“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease progression in PBC, in addition to alleviating quality of life-impacting symptoms,” Christelle Huguet, executive vice president of research and development at Ipsen, told Healio. “Elafibranor,